Skip to main content
Top
Published in: BMC Nephrology 1/2011

Open Access 01-12-2011 | Research article

Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study

Authors: Eric S Johnson, David H Smith, Micah L Thorp, Xiuhai Yang, Juhaeri Juhaeri

Published in: BMC Nephrology | Issue 1/2011

Login to get access

Abstract

Background

Previous studies of predictors of end-stage renal disease (ESRD) have limitations: (1) some focused on patients with clinically recognized chronic kidney disease (CKD); (2) others identified population-based patients who developed ESRD, but lacked earlier baseline clinical measures to predict ESRD. Our study was designed to address these limitations and to identify the strength and precision of characteristics that might predict ESRD pragmatically for decision-makers--as measured by the onset of renal replacement therapy (RRT).

Methods

We conducted a population-based, retrospective case-control study of patients who developed ESRD and started RRT. We conducted the study in a health maintenance organization, Kaiser Permanente Northwest (KPNW). The case-control study was nested within the adult population of KPNW members who were enrolled during 1999, the baseline period. Cases and their matched controls were identified from January 2000 through December 2004. We evaluated baseline clinical characteristics measured during routine care by calculating the adjusted odds ratios and their 95% confidence intervals after controlling for matching characteristics: age, sex, and year.

Results

The rate of RRT in the cohort from which we sampled was 58 per 100,000 person-years (95% CI, 53 to 64). After excluding patients with missing data, we analyzed 350 cases and 2,114 controls. We identified the following characteristics that predicted ESRD with odds ratios ≥ 2.0: eGFR<60 mL/min/1.73 m2 (OR = 20.5; 95% CI, 11.2 to 37.3), positive test for proteinuria (OR = 5.0; 95% CI, 3.5 to 7.1), hypertension (OR = 4.5; 95% CI, 2.5 to 8.0), gout/positive test for uric acid (OR = 2.5; 95% CI, 1.8 to 3.5), peripheral vascular disease (OR = 2.2; 95% CI, 1.4 to 3.6), congestive heart failure (OR = 2.1; 95% CI, 1.4 to 3.3), and diabetes (OR = 2.1; 95% CI, 1.5 to 2.9).

Conclusions

The clinical characteristics needed to predict ESRD--for example, to develop a population-based, prognostic risk score--were often documented during routine care years before patients developed ESRD and required RRT.
Literature
1.
go back to reference National Kidney Foundation: Executive Summary of the Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis. 2002, 39: S17-S31.CrossRef National Kidney Foundation: Executive Summary of the Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis. 2002, 39: S17-S31.CrossRef
2.
go back to reference Perneger TV, Whelton PK, Klag MJ: Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med. 1994, 331: 1675-79. 10.1056/NEJM199412223312502.CrossRefPubMed Perneger TV, Whelton PK, Klag MJ: Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med. 1994, 331: 1675-79. 10.1056/NEJM199412223312502.CrossRefPubMed
3.
go back to reference Fored CM, Ejerblad E, Lindblad P, et al: Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001, 345: 1801-08. 10.1056/NEJMoa010323.CrossRefPubMed Fored CM, Ejerblad E, Lindblad P, et al: Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001, 345: 1801-08. 10.1056/NEJMoa010323.CrossRefPubMed
4.
go back to reference Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS: Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009, 169: 342-50. 10.1001/archinternmed.2008.605.CrossRefPubMedPubMedCentral Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS: Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009, 169: 342-50. 10.1001/archinternmed.2008.605.CrossRefPubMedPubMedCentral
5.
go back to reference Iseki K, Ikemiya Y, Iseki C, Takishita S: Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant. 2003, 18: 899-905. 10.1093/ndt/gfg021.CrossRefPubMed Iseki K, Ikemiya Y, Iseki C, Takishita S: Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant. 2003, 18: 899-905. 10.1093/ndt/gfg021.CrossRefPubMed
6.
go back to reference Feldman HI, Appel LJ, Chertow GM, et al: The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol. 2003, 14: S148-S153. 10.1097/01.ASN.0000070149.78399.CE.CrossRefPubMed Feldman HI, Appel LJ, Chertow GM, et al: The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol. 2003, 14: S148-S153. 10.1097/01.ASN.0000070149.78399.CE.CrossRefPubMed
7.
go back to reference Rao M, Kausz AT, Mitchell D, et al: The Study of Treatment for Renal Insufficiency: Data and Evaluation (STRIDE), a national registry of chronic kidney disease. Semin Dial. 2002, 15: 366-9. 10.1046/j.1525-139X.2002.00088.x.CrossRefPubMed Rao M, Kausz AT, Mitchell D, et al: The Study of Treatment for Renal Insufficiency: Data and Evaluation (STRIDE), a national registry of chronic kidney disease. Semin Dial. 2002, 15: 366-9. 10.1046/j.1525-139X.2002.00088.x.CrossRefPubMed
8.
go back to reference Johnson ES, Thorp ML, Platt RW, et al: Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study. Am J Kidney Dis. 2008, 52: 653-660. 10.1053/j.ajkd.2008.04.026.CrossRefPubMed Johnson ES, Thorp ML, Platt RW, et al: Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study. Am J Kidney Dis. 2008, 52: 653-660. 10.1053/j.ajkd.2008.04.026.CrossRefPubMed
9.
go back to reference Selby J, Smith D, Johnson ES, et al: Kaiser Permanente Medical Care Program. Pharmacoepidemiology. Edited by: Strom BL. 2005, New York: John Wiley & Sons, 241-260. 4 Selby J, Smith D, Johnson ES, et al: Kaiser Permanente Medical Care Program. Pharmacoepidemiology. Edited by: Strom BL. 2005, New York: John Wiley & Sons, 241-260. 4
10.
go back to reference Rothman KJ, Greenland S, Lash TL: Case-Control Studies. Modern Epidemiology. Edited by: Rothman KJ, Greenland S, Lash TL. 2008, Philadelphia: Lippincott Williams & Wilkins, 111-127. 3 Rothman KJ, Greenland S, Lash TL: Case-Control Studies. Modern Epidemiology. Edited by: Rothman KJ, Greenland S, Lash TL. 2008, Philadelphia: Lippincott Williams & Wilkins, 111-127. 3
11.
go back to reference Smith LR, Harrell FE, Muhlbaier LH: Problems and potentials in modelling survival. Medical Effectiveness Research Data Methods (Summary Report). Edited by: Grady ML, Schwartz. 1992, Rockville, MD: US Dept of HHS, 151-159. Smith LR, Harrell FE, Muhlbaier LH: Problems and potentials in modelling survival. Medical Effectiveness Research Data Methods (Summary Report). Edited by: Grady ML, Schwartz. 1992, Rockville, MD: US Dept of HHS, 151-159.
12.
13.
go back to reference Greenland S, Finkle WD: A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995, 142: 1255-1264.PubMed Greenland S, Finkle WD: A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995, 142: 1255-1264.PubMed
14.
go back to reference United States Renal Data Systems: Incidence and Prevalence (Chapter 2). In: Atlas of End-Stage Renal Disease (Volume 2): USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2010, Bethesda, Maryland: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 253-66. United States Renal Data Systems: Incidence and Prevalence (Chapter 2). In: Atlas of End-Stage Renal Disease (Volume 2): USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2010, Bethesda, Maryland: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 253-66.
15.
go back to reference Perneger TV, Brancati FL, Whelton PK, et al: Studying the causes of kidney disease in humans: a review of methodologic obstacles and possible solutions. Am J Kidney Dis. 1995, 25: 722-731. 10.1016/0272-6386(95)90548-0.CrossRefPubMed Perneger TV, Brancati FL, Whelton PK, et al: Studying the causes of kidney disease in humans: a review of methodologic obstacles and possible solutions. Am J Kidney Dis. 1995, 25: 722-731. 10.1016/0272-6386(95)90548-0.CrossRefPubMed
Metadata
Title
Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study
Authors
Eric S Johnson
David H Smith
Micah L Thorp
Xiuhai Yang
Juhaeri Juhaeri
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2011
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-12-17

Other articles of this Issue 1/2011

BMC Nephrology 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine